Bone Biologics Corp (BBLG) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US0980706008

Price
0.33 USD
Market cap
1.10 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-57.81 %
Return on assets (ROA)
-53.64 %

Bone Biologics Corp financials

Fiscal year20242025
Operating income-4.22 m USD-3.23 m USD
EBIT-4.11 m USD-3.11 m USD
Net income-4.11 m USD-3.11 m USD
Diluted EPS – continuing operations-4.83 USD-2.65 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Bone Biologics Corp

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.